Company profile
ARDELYX, INC.
NASDAQ:ARDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TENAPANOR HYDROCHLORIDE | approved | — | 3 | approved |
| TENAPANOR | phase2_3 | — | 9 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06553547 | phase2 | completed | 2024-07-24 | 2026-07-07 | Ardelyx | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
| NCT02621892 | phase3 | completed | 2015-10-01 | 2017-03-01 | Ardelyx | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C |
| NCT02686138 | phase3 | completed | 2015-12-01 | 2017-08-01 | Ardelyx | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C |
| NCT07382167 | phase3 | recruiting | 2026-01-13 | 2027-02-26 | Ardelyx | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults |
| NCT02727751 | phase3 | completed | 2016-03-01 | 2017-10-01 | Ardelyx | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 211801 | NDA | ARDELYX INC | ||||
Loading… | ||||||
| NDA 213931 | NDA | ARDELYX INC | ||||
Loading… | ||||||